Gossamer Bio, Inc. (GOSS) NASDAQ

Currency In USD

Gossamer Bio, Inc.

Address

3115 Merryfield Row

San Diego, CA 92121

United States of America (the)

Phone

858 684 1300

Website

https://www.gossamerbio.com

Sector

Healthcare

Industry

Biotechnology

Employees

162

First IPO Date

February 08, 2019

Key Executives

Name	Title	Pay	Year Born
Faheem Hasnain	Co-Founder, Chief Executive Officer, President & Chairman	908,449	1958
Christian Waage	Executive VP, General Counsel & Secretary	583,156	1967
Robert Smith	Chief Commercial Officer	663,713	1969
Bryan Giraudo	Chief Operating Officer & Chief Financial Officer	676,743	1975
Richard Aranda	Chief Medical Officer	677,492	1960
Kelly Dawson	Senior Vice President of Program Team Lead	0	N/A
Matt Cravets	Senior Vice President of Biometrics	0	N/A
Caryn L. Peterson	Chief Development Officer	0	1959
Jeanine Anthony	Senior Vice President of Marketing	0	N/A
Deanna Weber	Executive Vice President of Human Resources	0	N/A
Robert F. Roscigno	Senior Vice President of Clinical Development of Pulmonary Vascular Disease	0	1966
Conor O'Donovan	Senior Vice President of Regulatory Affairs	0	N/A
Jeff Boerneke	General Counsel & Secretary	0	N/A
Louis K. Cherico	Senior Vice President of Finance & Treasury	0	N/A

Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.